紫杉醇化疗在宫颈癌中的临床应用

紫杉醇为广谱有效的抗实体瘤药物，用于宫颈癌患者治疗已进行广泛临床研究，证实其可靠有效。从单药、双药及三药化疗等方面，综述近年紫杉醇治疗宫颈癌的临床应用。紫杉醇（T）联合顺铂（P）或卡铂（C）化疗方案优于紫杉醇单药或三药化疗，安全有效。尤其在新辅助化疗中；与顺铂相比，卡铂肾毒性小，无需水化，TC方案相对简单；TP或TC配合放疗疗效显著；紫杉醇周疗与3周疗法比较疗效类似，不良反应较小。

Paclitaxel Chemothrepy for Cervical Cancer

The anti-tumour agent paclitaxel has proved to be effective for the treatment of patients with solid tumor, and recently many results also indicate it’s clinically highly effective in patients with cervical cancer. Paclitaxel chemotherapy for cervical cancer is reviewed in three directions including monochemotherapy, and two or three drugs combination chemotherapy. The regimen of paclitaxel（T） combined with cisplatin（P） or carboplatin（C） has proved highly effective and safe, showing it is superior to monotherapy or three drugs combination therapy, especially in neoadjuvant chemotherapy. Compared with TP, TC demonstrates easiness of administration for improved renal toxicity of carboplatin. TP or TC combining with radiotherapy shows significant effect. Weekly paclitaxel has similar response rate and less adverse reaction versus the standard 3-weekly paclitaxel. Paclitaxel chemothrepy would be more popular for cervical cancer patients.